AFFiRiS 
Welcome,         Profile    Billing    Logout  
 7 Products   14 Diseases  7 Products   0 Trials   38 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alhydrogel injectable (AD04) / ADvantage Therap
2022-003532-73: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE Multicentrické, randomizované, placebom-kontrolované, dvojito zaslepené klinické skúšanie fázy 2b na stanovenie bezpečnosti a účinnosti produktu AD04 u pacientov s včasnou Alzheimerovou chorobou – ADVANCE

Not yet recruiting
2
122
Europe, RoW
AD04, AD04, Solution for injection
ADvantage Therapeutics GmbH, ADvantage Therapeutics GmbH
early Alzheimer’s disease, early Alzheimer’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
AT04 / AFFiRiS
No trials found
Affitope AT06A + adjuvant / AFFiRiS
No trials found
PD04 / AFFiRiS
No trials found
PD01/PD04+AD05 / AFFiRiS
No trials found
C6-17 / AFFiRiS
No trials found
Undisclosed Bi-epitopic therapeutic / AFFiRiS
No trials found

Download Options